Hot Sliver Companies To Invest In 2015

Private equity investor Warburg Pincus has been a shareholder in term life insurance underwriter Primerica  (NYSE: PRI  ) since its IPO in 2010. However, the financial products marketer will be buying back all of the holdings Warburg Pincus owns for $154.7 million. That translates into almost 2.5 million shares of common stock and warrants that  are exercisable for 4.1 million shares.

The purchase price was determined based on the closing price of Primerica common stock on May 28, and following the transaction, Warburg Pincus will no longer own any of Primerica’s outstanding common stock.

Primerica will purchase for $34.67 per share all of the stock beneficially owned by Warburg Pincus Private Equity X and Warburg Pincus X Partners. It will also pay $16.67 per underlying share for the warrants they hold.

In a press release dated Tuesday, Primerica Chairman and Co-CEO Rick Williams said: “Today’s transaction marks the conclusion of Primerica’s IPO era. Warburg Pincus has been a great partner and was vital in helping us become a strong public company. In three years, our Company has completed an exit from Citigroup, and, with today’s acquisition of Warburg Pincus’ stake, we become a ‘fully’ public company.”

Hot Sliver Companies To Invest In 2015: Oxygen Biotherapeutics Inc.(OXBT)

Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.

Advisors’ Opinion:

  • [By Bryan Murphy]

    To say that Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) has made its presence known over the past three weeks would be an understatement. It would be more accurate and fairer to say OXBT been an “in your face” kind of name that you couldn’t look past even if you wanted to. Rather than continue to sidestep it, care to stop, invest two minutes of time, and get the Q&D version of what’s really going on here? If so, read on.

  • [By Paul Ausick]

    Stocks on the Move: GT Advanced Technologies Inc. (NASDAQ: GTAT) is up 20.5% at $10.10 after earnings and signing deal to supply Apple Inc. (NASDAQ: AAPL) with sapphire glass. Marvell Technology Group Ltd. (NASDAQ: MRVL) is up 8.5% at $13.03 following reports of an investment by KKR & Co. (NYSE: KKR). Oxygen Biotherapeutics Inc. (NASDAQ: OXBT) is up 62.7% at $8.38 along with other biotech stocks making big moves today.

Hot Sliver Companies To Invest In 2015: Federal Home Loan Mortgage Corp (FMCC)

Federal Home Loan Mortgage Corporation (Freddie Mac) conducts business in the United States residential mortgage market and the global securities market. The Company operates in three segments: Single-family Guarantee, Investments, and Multifamily. The Single-family Guarantee segment reflects results from the Company’s single-family credit guarantee activities. The Investments segment reflects results from the Company’s investment, funding and hedging activities. The Multifamily segment reflects results from the Company’s investment (both purchases and sales), securitization, and guarantee activities in multifamily mortgage loans and securities. The Company conducts its operations in the United States and its territories.

Single-Family Guarantee Segment

In the Company’s Single-family Guarantee segment, it purchases single-family mortgage loans originated by the Company’s seller/servicers in the primary mortgage market. The Company uses the mo rtgage securitization process to package the purchased mortgage loans into guaranteed mortgage-related securities. The Company guarantees the payment of principal and interest on the mortgage-related security in exchange for management and guarantee fees. The Company’s customers are lenders in the primary mortgage market that originate mortgages for homeowners. These lenders include mortgage banking companies, commercial banks, savings banks, community banks, credit unions, Housing Finance Agency (HFAs), and savings and loan associations. The Company’s customers also service loans in its single-family credit guarantee portfolio.

Mortgage securitization is a process, by which the Company purchase mortgage loans that lenders originate, and pool these loans into mortgage securities that are sold in global capital markets. The United States residential mortgage market consists of a primary mortgage market that links homebuyers and lenders and a secondary mortga ge market that links lenders and investors. The Company part! icipates in the secondary mortgage market by purchasing mortgage loans and mortgage-related securities for investment and by issuing guaranteed mortgage-related securities. In the Single-family Guarantee segment, it purchase and securitize single-family mortgages, which are mortgages that are secured by one- to four-family properties. The types of mortgage-related securities it issue and guarantee include PCs, REMICs and Other Structured Securities and Other Guarantee Transactions. The Company also issue mortgage-related securities to third parties in exchange for non-Freddie Mac mortgage-related securities. The non-Freddie Mac mortgage-related securities are transferred to trusts that were specifically created for the purpose of issuing securities, or certificates, in the Other Guarantee Transactions.

Investments Segment

In the Company’s Investments segment, it invests principally in mortgage-related securities and single-family performing mortga ge loans, which are funded by other debt issuances and hedged using derivatives. In the Company’s Investments segment, it also provides funding and hedging management services to the Single-family Guarantee and Multifamily segments. The Company’s customers for its debt securities predominantly include insurance companies, money managers, central banks, depository institutions, and pension funds. The Company funds its investment activities by issuing short-term and long-term debt. The Company’s PCs are an integral part of its mortgage purchase program. The Company’s Single-family Guarantee segment purchases many of its mortgages by issuing PCs in exchange for those mortgage loans in guarantor swap transactions. The Company also issue PCs backed by mortgage loans that it purchased for cash.

Multifamily Segment

The Company’s multifamily segment issues Other Structured Securities, but does not issue REMIC securities. The Company multifamily s egment also enters into other guarantee commitments for mult! ifamily H! FA bonds and housing revenue bonds held by third parties. The Company acquires a portion of its multifamily mortgage loans from several large seller/servicers.

The Company competes with Federal National Mortgage Association (Fannie Mae), Government National Mortgage Association (Ginnie Mae), Mae Federal Housing Administration/the United States Department of Veteran Affairs (FHA/VA) and Federal Home Loan Bank (FHLB).

Advisors’ Opinion:

  • [By Dimitra DeFotis]

    Investor Bill Ackman, who knows a thing or two about real estate, just made the case for reforming Fannie Mae (FNMA) and Freddie Mac (FMCC) but keeping them independent of government control.

  • [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]

    Bank of America Corp.(BAC) on Wednesday said it would pay about $9.5 billion to settle all litigation by a top U.S. federal regulator over mortgage securities sold to Fannie Mae(FNMA) (FNMA) and Freddie Mac(FMCC) (FMCC). Shares edged up 13 cents to $17.31 premarket.

  • [By Ben Levisohn]

    The S&P 500 fell 0.5% to 1,867.63, while the Dow Jones Industrial Average dropped 0.4% to 16,351.25. Goldman Sachs fell 2.1% to $169.89 today (weakness in commodities hitting the investment banks?), while United Technologies declined 1.8% to $115.64 and E.I. du Pont de Nemours dropped 2% to $66.01 after it said that bad weather and turmoil in the Ukraine would hit earnings. Fannie Mae (FNMA) fell 31% and Freddie Mac (FMCC) dropped 27% after leaders of the Senate banking committee Senate agreed on a plan to wind them down.

Hot Sliver Companies To Invest In 2015: Delta Air Lines Inc (DAL)

Delta Air Lines, Inc. (Delta) provides scheduled air transportation for passengers and cargo throughout the United States and around the world. The Company’s route network gives it a presence in every domestic and international market. Delta’s route network is centered around the hub system it operate at airports in Amsterdam, Atlanta, Cincinnati, Detroit, Memphis, Minneapolis-St. Paul, New York-JFK, Paris-Charles de Gaulle, Salt Lake City and Tokyo-Narita. Each of these hub operations includes flights that gather and distribute traffic from markets in the geographic region surrounding the hub to domestic and international cities and to other hubs. The Company’s network is supported by a fleet of aircraft that is varied in terms of size and capabilities.

Delta has bilateral and multilateral marketing alliances with foreign airlines to improve its access to international markets. These arrangements can include code-sharing, reciprocal frequent flyer progr am benefits, shared or reciprocal access to passenger lounges, joint promotions, common use of airport gates and ticket counters, ticket office co-location, and other marketing agreements. Its international code-sharing agreements enable it to market and sell seats to an expanded number of international destinations. The Company has international codeshare arrangements with Aeromexico, Air France, Air Nigeria, Alitalia, Aeroflot, China Airlines, China Eastern, China Southern, CSA Czech Airlines, KLM Royal Dutch Airlines, Korean Air, Olympic Air, Royal Air Maroc, VRG Linhas Aereas (operating as GOL), Vietnam Airlines, Virgin Australia and WestJet Airlines.

In addition to the Company’s marketing alliance agreements with individual foreign airlines, it is a member of the SkyTeam airline alliance. Delta also has frequent flyer and reciprocal lounge agreements with Hawaiian Airlines, and codesharing agreements with American Eagle Airlines (American Eagle) and Hawai ian Airlines. It has air service agreements with multiple do! mestic regional air carriers that feed traffic to its route system by serving passengers primarily in small-and medium-sized cities.

Through the Company’s regional carrier program, it has contractual arrangements with 10 regional carriers to operate regional jet and, in certain cases, turbo-prop aircraft using its DL designator code. In addition to Delta’s wholly owned subsidiary, Comair, it has contractual arrangements with ExpressJet Airlines, Inc. and SkyWest Airlines, Inc., both subsidiaries of SkyWest, Inc.; Chautauqua Airlines, Inc. and Shuttle America Corporation, both subsidiaries of Republic Airways Holdings, Inc.; Pinnacle Airlines, Inc. and Mesaba Aviation, Inc. (Mesaba), both subsidiaries of Pinnacle Airlines Corp. (Pinnacle); Compass Airlines, Inc. (Compass) and GoJet Airlines, LLC, both subsidiaries of Trans States Holdings, Inc. (Trans States), and American Eagle.

The Company’s SkyMiles program allows program members to earn mil eage for travel awards by flying on Delta, Delta’s regional carriers and other participating airlines. Mileage credit may also be earned by using certain services offered by program participants, such as credit card companies, hotels and car rental agencies. In addition, individuals and companies may purchase mileage credits. The Company reserves the right to terminate the program with six months advance notice, and to change the program’s terms and conditions at any time without notice.

SkyMiles program mileage credits can be redeemed for air travel on Delta and participating airlines, for membership in the Company’s Delta Sky Clubs and for other program participant awards. Mileage credits are subject to certain transfer restrictions and travel awards are subject to capacity controlled seating. During the year ended December 31, 2011, program members redeemed more than 275 billion miles in the SkyMiles program for more than 12 million award redemptions. D uring 2011, 8.2% of revenue miles flown on Delta were from a! ward trav! el.

The Company generates cargo revenues in domestic and international markets through the use of cargo space on regularly scheduled passenger aircraft. Delta is a member of SkyTeam Cargo, an airline cargo alliance. SkyTeam Cargo offers a network spanning six continents and provides customers an international product line.

The Company has several other businesses arising from its airline operations, including aircraft maintenance, repair and overhaul (MRO); staffing services for third parties; vacation wholesale operations, and its private jet operations. Delta’s MRO operation, known as Delta TechOps, is an airline MRO in North America. In addition to providing maintenance and engineering support for its fleet of approximately 775 aircraft, Delta TechOps serves more than 150 aviation and airline customers. Its staffing services business, Delta Global Services, provides staffing services, professional security, training services and aviation soluti ons to approximately 150 customers. The Company’s vacation wholesale business, MLT Vacations, is the provider of vacation packages in the United States. Its private jet operations, Delta Private Jets, provides aircraft charters, aircraft management and programs allowing members to purchase flight time by the hour.

The Company competes with SkyTeam, United Air Lines, Continental Airlines, Lufthansa German Airlines, Air Canada, American Airlines, British Airways and Qantas.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Delta Air Lines (DAL) is flying high this year, but that can’t stop Morgan Stanley’s John Godyn and team shouting their love for stock from the rooftops.

    Shares of Delta Air Lines have gained 37% this year, topping Southwest Airlines’ (LUV) 29% rise, United Continental’s (UAL) 6.6% advance and JetBlue’s (JBLU) 1.2% increase. American Airlines (AAL) has gained 52% so far in 2014.

    Godyn explains why he thinks Delta Air Lines remains the cream of the crop:

    Today, many we speak to believe that Delta Air Lines’ advantages are primarily a function of where the company is in its post-M&A lifecycle of sorts rather than representative of apersistent, unique set of competencies, assets, processes, and cultural factors. After our most recent round of meetings with mgmt this week and last – we can’t help but increasingly believe the latter.

    In a nutshell, we feel slightly more confident in DAL’s non-fare revenue opportunities and ability to maintain sub-inflationary [cost per available seat miles] ex-Fuel growth in 2015 and as a result raise our current 2015 EPS estimate of $3.90 to $4.00 – reaffirming our Street-high stance.

    Wolfe Research’s Hunter Keay and Jared Shojaian thinks JetBlue should add more seats:

    One area where we believe JBLU has an opportunity to improve earnings is cabin densification. Simply put we think JBLU doesn’t have enough inventory for sale. The concept of flying planes with 34” of legroom in coach is an idea that’s not only shunned by the most profitable airlines in the country, but it’s also one that has failed in the past. American tried it and failed 15 years ago – what makes JBLU so different?

    Southwest Airlines…perhaps a comp for JBLU considering Southwest Airlines’ customer service focus, operates its B737-700s with 31” of pitch. If JBLU converted all its A320 coach seats to Southwest Airlines’ B737-700 se

  • [By Alexander MacLennan]

    Among major carriers, Delta Air Lines (NYSE: DAL  ) has proved to be a standout over the past few years. Not only is the Atlanta-based carrier producing record profits but it’s also become the only one of the big three legacy carriers to pay a dividend or join the S&P 500 Index.


    Getty Images @Lebeaucarnews Here’s something those trying to cash in on frequent flyer miles or points seldom hear: It’s now easier to book the flight you want to the destination you want. The annual Switchfly Reward Seat Availability Survey, which gauges the frequent flyer programs at 25 of the world’s largest airlines, found seats were available for frequent flyer redemption on 72.4 percent of the flights checked. That’s a 1.3 percent increase compared with the prior year. “I was surprised by this year’s results,” said Jay Sorensen, president of IdeaWorks consulting firm, which surveyed 7,640 flights in March. “Typically, when you see the industry recovering from financial duress, one of the things they cut back on is giving away free seats.” Instead, many airlines have actually made frequent flyer seats available on more of their flights. Sorensen credits the boost to the independent credit cards many flyers now use to rack up award miles that they can redeem without restrictions. Those credit cards, like the one offered by Capitol One, have become popular with consumers, and have forced airlines to make it easier for members of their own frequent flyer programs to cash in miles or points in order to compete. “[The airlines] want to compete against the bank-issued credit cards, so this is one way for them to do that,” Sorensen said. Another factor is an accounting rule that says airlines can book revenue from the sale of frequent flyer miles only after the passenger has traveled. Low-cost carriers offer the most options As has been the case in past years, low-cost carriers have the most flights offering seats for frequent flyer redemption, according to the study. On average, 95.8 percent of the low-cost airline flights surveyed had seats available. By comparison, traditional airlines had frequent flyer award seats on 65 percent of their flights. That’s up 4 percent from last year, but still well below the availability offered by low-cost airlin

Hot Sliver Companies To Invest In 2015: OncoMed Pharmaceuticals Inc (OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company’s anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.

Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia tri al in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.

Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.

The Company utilizes several robust technologies for th e discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.

Advisors’ Opinion:

  • [By Stephen Quickel]

    Recently, too, Celgene has formed a strategic partnership with OncoMed (OMED) to develop up to six anti-cancer stem-cell antibodies.

    Celgene itself has posted four successive quarters of revenue growth, which is expected to lift annual sales from $5.5 to $6.4 billion for calendar 2013, and to $7.5 billion in 2014. Despite its expanding size, earnings per share are projected to grow by 23.2% a year, by 28 Street analysts following its stock.

  • [By Jake L’Ecuyer]

    Equities Trading UP
    OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46.

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)

Hot Sliver Companies To Invest In 2015: Tribune Co (TRBAA)

Tribune Company, incorporated on March 19, 1968, is a media and entertainment company engaged in newspaper publishing, television and radio broadcasting and entertainment through its subsidiaries. The Company’s operations are divided into two industry segments: publishing and broadcasting and entertainment. In publishing, the Company’s daily newspapers include the Los Angeles Times, Chicago Tribune, The Baltimore Sun, Sun Sentinel (South Florida), Orlando Sentinel, Hartford Courant, The Morning Call and Daily Press. The company’s broadcasting group operates 23 television stations, WGN America on national cable and Chicago’s WGN-AM.


The Company’s broadcasting owns and operates 23 major-market television stations and reaches more than 80% of United States television households. The group is anchored by WGN America, which can be seen in more than 70 million United States households via cable and satellite services. 13 Tribune stations are affiliates of The CW. Seven are FOX affiliates.


The Company’s newspapers include the Los Angeles Times and Chicago Tribune. Tribune Media Services specializes in entertainment listings and syndication, providing news and information for print, broadcast and interactive media.

Tribune Digital

Tribune Digital manages the operations of Tribune’s daily newspapers and their associated Websites, plus all aspects of the Company’s classified advertising operations, as well as Websites for Tribune’s TV stations. Its national classified sites include, and

Advisors’ Opinion:

  • [By Michael Lewis]

    The owner of the Los Angeles Times, and recent bankruptcy court emergent, Tribune  (NASDAQOTH: TRBAA  )  has made some interesting moves since its downfall in 2008, when the company drowned under the weight of its $13 billion debt load — a parting gift from a leveraged buyout a year earlier. This week, the story got even more interesting, as management announced that the company would split its profitable operations (TV), and its less appealing businesses (papers), into two separate entities. While more details need to emerge before we can determine whether the company is a worthwhile investment, this unloved company could present an interesting opportunity to sophisticated investors.

  • [By Tim Brugger]

    Murray McQueen has been named to the newly created position of president, real estate, to oversee Tribune’s (NASDAQOTH: TRBAA  ) “valuable portfolio of more than seven million square feet of real estate assets,” the company announced today. McQueen will take over his new role effective immediately.

Hot Sliver Companies To Invest In 2015: Mining Minerals of Mexico Corp (WIIM)

Mining Minerals of Mexico, Corp., formerly Cal Alta Auto Glass, Inc., incorporated on October 14, 1999, specializes in the repair and replacement of damaged glass windows on automobiles, including recreational vehicles (RVs) and Motorhomes. The Company uses only factory-authorized glass. It specializes in all foreign and domestic makes and models.

The Company uses other equipment manufacturer (O.E.M.)-rated adhesives and rust inhibiting primer’s (manufactured by Dow Automotive). Based in Canada, it has two Auto Glass facilities servicing its customers. The Company stocks its own windshields at each of its locations throughout Calgary.

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap mining stocks International Star Inc (OTCMKTS: ILST) and Mining Minerals of Mexico Corp (OTCMKTS: WIIM) sank 13.33% and 24.9%, respectively, today, with at least one of these small cap stocks being the subject of paid promotions or investor relations type of activities while the other has had no news since last summer. So should you dig into these small cap mining stocks which just dug a hole for investors and traders alike? Here is a closer look to help you decide:

Hot Sliver Companies To Invest In 2015: Enphase Energy Inc (ENPH)

Enphase Energy, Inc. (Enphase), incorporated in March 20, 2006, designs, develops and sells microinverter systems for the solar photovoltaic industry. The Company sells its microinverter systems primarily to distributors who resell them to solar installers. It also sells directly to installers, as well as through original equipment manufacturers (OEMs). The Company’s microinverter system consists of three components: Enphase microinverter, Envoy communications gateway and Enlighten Web-based software.

Enphase Microinverter

The Company’s Enphase microinverter delivers power conversion at the individual solar module level by introducing a digital architecture that incorporates custom application specific integrated circuits (ASICs) power electronics devices and an embedded software subsystem. A residential solar installation consists of 5 to 50 microinverters; a small commercial solar installation consists of 50 to 500 microinverters, and mediu m or larger commercial solar installation consists of 500 to 10,000 microinverters, or more.

Envoy Communications Gateway

The Company’s Envoy communications gateway is installed in the system owner’s home or business and serves as a networking hub that collects data from the microinverter array and sends the information to its hosted data center. One Envoy is typically sold with each solar installation and can support up to 500 Enphase microinverters.

Enlighten Software

The Company’s Enlighten Web-based software collects and analyzes this information to enable system owners to monitor and realize the performance of their solar photovoltaics (PV) system and also provides an online portal designed for installers to enable them to track and manage all of their Enphase enabled projects and monitor and analyze the performance of their installed systems.

The Company competes with SMA Solar Technology AG, Fron ius International GmbH, Power-One, Inc., SunPower Corp.

Advisors’ Opinion:

  • [By Zacks]

    Other stocks from the sector worth considering are Enphase Energy, Inc. (NASDAQ: ENPH), First Solar, Inc. (NASDAQ: FSLR) and Trina Solar Limited (NYSE: TSL).  All these stocks currently carry a Zacks Rank #2 (Buy). 

  • [By Seth Jayson]

    There’s no foolproof way to know the future for Enphase Energy (Nasdaq: ENPH  ) or any other company. However, certain clues may help you see potential stumbles before they happen — and before your stock craters as a result.

Hot Sliver Companies To Invest In 2015: Cray Inc(CRAY)

Cray Inc. engages in the design, development, manufacture, marketing, and service of high-performance computing (HPC) systems, known as supercomputers. Its product line includes Cray XE6 system, a massively parallel processing system; Cray XE6m supercomputer that incorporates its Cray Gemini network; Cray XMT supercomputer, a scalable massively multithreaded platform with a shared memory architecture that is suited for tasks, such as pattern matching, complex searches, scenario development, behavioral prediction, anomaly identification, and graph analysis; and Cray CX1 and CX1000 systems that are purpose-built for laboratories and university departments. The company?s products under development comprise Cray XE6 System enhancements; and next generation Cray XMT System. It also offers engineering services related to HPC systems and solutions, such as maintenance support services and technology-led professional services. Cray Inc. provides its products and services to gover nment agencies, academic institutions, and commercial entities in the United States, Canada, Europe, Japan, and the Asia-Pacific. The company was formerly known as Tera Computer Company and changed its name to Cray Inc. in 2000. Cray Inc. was founded in 1987 and is headquartered Seattle, Washington.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Equities Trading UP
    Cray (NASDAQ: CRAY) rose on Friday’s session, gaining a staggering 36.87 percent to $41.02 after beating on the top and bottom lines, while boosting its fiscal year guidance.

  • [By Lisa Levin]

    Cray (NASDAQ: CRAY) surged 14.40% to $31.07. The volume of Cray shares traded was 649% higher than normal. Cray affirmed its revenue outlook for 2013 and 2014.

  • [By Michael A. Robinson]

    The charting approach we use to find low-priced, fast-moving tech shares, my Real Demand Tracking System, is set up to find stocks like:

    Santarus Inc. (Nasdaq: SNTS): Shares of this small-cap biotech firm have gained 835% over the past five years. Cray Inc. (Nasdaq: CRAY): This small-cap leader in high-performance computing gave shareholders a five-year return of 855%. Align Technology Inc. (Nasdaq: ALGN): Over the past five years, share of this mid-cap medical device firm are up some 720%.

    As impressive as these gains are, the opportunity I’m closely watching today could be among the greatest we’ll see in our lifetimes.

Hot Sliver Companies To Invest In 2015: iShares Government/Credit Bond ETF (GBF)

iShares Lehman Government/Credit Bond Fund (the Fund) seeks investment results that correspond to the price and yield performance of the United States Government and investment-grade United States corporate securities of the United States bond market as defined by the Lehman Brothers U.S. Government/Credit Index (the Index). The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index.

The Index measures the performance of United States dollar-denominated United States Treasuries, government-related securities and investment-grade United States corporate securities that have a remaining maturity of greater than or equal to one year, and have more than $250 million or more of outstanding face value. The securities must be fixed-rate and non-convertible securities.

Advisors’ Opinion:

  • [By Jonathan Morgan]

    Bilfinger SE (GBF) climbed 3.1 percent to 74.30 euros. Germany’s second-largest builder predicted a significantly stronger second half after reporting second-quarter net income of 47 million euros ($62.5 million), which was in line with analysts’ estimates.

Hot Sliver Companies To Invest In 2015: Salix Pharmaceuticals Ltd (SLXP)

Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company’s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Xifaxan (rifaximin) tablets

Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers’ diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.

It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.

In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla’s application related to amorphous rifaximin and Solmag SpA’s application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in ad dition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.

MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution

MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.

Apriso (mesalamine) extended-release capsu les 0.375 gram

Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product’s prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.

Relistor (methylnaltrexone bromide)

Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.

OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets

Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.


Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.


Deflux i s a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.

Fulyzaq (crofelemer) delayed-release tablets

On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.

Giazo (balsalazide disodium) tablets

February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.

Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets

METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.

Azasan (azathioprine) tablets

Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.

Anusol-HC and Proctocort (hydrocortisone) creams and suppositories

The Company acquired t he right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.

Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)

Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.

Colazal (balsalazide disodium) capsules

The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.

The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.

Advisors’ Opinion:

  • [By David Williamson]

    In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP  ) of Santarus (NASDAQ: SNTS  ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.

  • [By Jake L’Ecuyer]

    Equities Trading UP
    Santarus (NASDAQ: SNTS) shot up 37.95 percent to $32.03 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.